MannKind Corp (MNKD)vsMerck & Company Inc (MRK)
MNKD
MannKind Corp
$3.75
-1.06%
HEALTHCARE · Cap: $1.27B
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 16812% more annual revenue ($66.57B vs $393.63M). MRK leads profitability with a 4.8% profit margin vs -11.1%. MRK appears more attractively valued with a PEG of 2.64. MRK earns a higher WallStSmart Score of 36/100 (F).
MNKD
Avoid33
out of 100
Grade: F
MRK
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MNKD.
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 42.9% year-over-year
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Weak financial health signals
Expensive relative to growth rate
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : MNKD
The strongest argument for MNKD centers on Revenue Growth, Debt/Equity. Revenue growth of 42.9% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bear Case : MNKD
The primary concerns for MNKD are Market Cap, Return on Equity, Piotroski F-Score.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
MNKD profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
MNKD carries more volatility with a beta of 1.10 — expect wider price swings.
MNKD is growing revenue faster at 42.9% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (36/100 vs 33/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
MannKind Corp
HEALTHCARE · BIOTECHNOLOGY · USA
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutics for endocrine and orphan lung diseases in the United States. The company is headquartered in Westlake Village, California.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?